期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 18, 期 5, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2022.2055417
关键词
Glioblastoma; immunotherapy; chimeric antigen receptor (CAR) T cell; oncolytic virus
资金
- Science and Technology Department of Sichuan Province, P.R. China [2017SZ0015]
- National Natural Science Foundation of China [82073404]
Glioblastoma is a common and aggressive form of brain tumor with poor prognosis. Immunotherapy has shown promise in treating glioblastoma.
Glioblastoma (GBM) stands out as the most common, aggressive form of primary malignant brain tumor conferring a devastatingly poor prognosis. Despite aggressive standard-of-care in surgical resection and chemoradiation with temozolomide, the median overall survival of patients still remains no longer than 15 months, due to significant tumor heterogeneity, immunosuppression induced by the tumor immune microenvironment and low mutational burden. Advances in immunotherapeutic approaches have revolutionized the treatment of various cancer types and become conceptually attractive for glioblastoma. In this review, we provide an overview of the basic knowledge underlying immune targeting and promising immunotherapeutic strategies including CAR T cells, oncolytic viruses, cancer vaccines, and checkpoint blockade inhibitors that have been recently investigated in glioblastoma. Current clinical trials and previous clinical trial findings are discussed, shedding light on novel strategies to overcome various limitations and challenges.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据